CYLD deletion triggers nuclear factor-κB-signaling and increases cell death resistance in murine hepatocytes.

AIM To analyze the role of CYLD for receptor-mediated cell death of murine hepatocytes in acute liver injury models. METHODS Hepatocyte cell death in CYLD knockout mice (CYLD(-/-) ) was analyzed by application of liver injury models for CD95- (Jo2) and tumor necrosis factor (TNF)-α- [D-GalN/lipopolysaccharide (LPS)] induced apoptosis. Liver injury was assessed by measurement of serum transaminases and histological analysis. Apoptosis induction was quantified by cleaved PARP staining and Western blotting of activated caspases. Nuclear factor (NF)-κB, ERK, Akt and jun amino-terminal kinases signaling were assessed. Primary Hepatocytes were isolated by two step-collagenase perfusion and treated with recombinant TNF-α and with the CD95-ligand Jo2. Cell viability was analyzed by MTT-assay. RESULTS Livers of CYLD(-/-) mice showed increased anti-apoptotic NF-κB signaling. In both applied liver injury models CYLD(-/-) mice showed a significantly reduced apoptosis sensitivity. After D-GalN/LPS treatment CYLD(-/-) mice exhibited significantly lower levels of alanine aminotransferase (ALT) (295 U/L vs 859 U/L, P < 0.05) and aspartate aminotransferase (AST) (560 U/L vs 1025 U/L, P < 0.01). After Jo injection CYLD(-/-) mice showed 2-fold lower ALT (50 U/L vs 110 U/L, P < 0.01) and lower AST (250 U/L vs 435 U/L, P < 0.01) serum-levels compared to WT mice. In addition, isolated CYLD(-/-) primary murine hepatocytes (PMH) were less sensitive towards death receptor-mediated apoptosis and showed increased levels of Bcl-2, XIAP, cIAP1/2, survivin and c-FLIP expression upon TNF- and CD95-receptor triggering, respectively. Inhibition of NF-κB activation by the inhibitor of NF-κB phosphorylation inhibitor BAY 11-7085 inhibited the expression of anti-apoptotic proteins and re-sensitized CYLD(-/-) PMH towards TNF- and CD95-receptor mediated cell death. CONCLUSION CYLD is a central regulator of apoptotic cell death in murine hepatocytes by controlling NF-κB dependent anti-apoptotic signaling.

[1]  M. Coumar,et al.  Treat cancers by targeting survivin: just a dream or future reality? , 2013, Cancer treatment reviews.

[2]  L. Tang,et al.  Role of β-Catenin in regulating the balance between TNF-α- and Fas-induced acute liver injury. , 2013, Cancer letters.

[3]  E. Jankowska,et al.  The proteasome in health and disease. , 2012, Current pharmaceutical design.

[4]  Jennifer Y. Zhang,et al.  CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways , 2012, The Journal of investigative dermatology.

[5]  J. Timmer,et al.  A Systems Biology Study on NFκB Signaling in Primary Mouse Hepatocytes , 2012, Front. Physio..

[6]  D. Jäger,et al.  Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. , 2012, Journal of hepatology.

[7]  G. Kollias,et al.  Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. , 2012, Cancer cell.

[8]  P. Bourne,et al.  CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt , 2012, Nature Communications.

[9]  Ramin Massoumi,et al.  CYLD: a deubiquitination enzyme with multiple roles in cancer. , 2011, Future oncology.

[10]  P. Galle,et al.  Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. , 2010, International journal of oncology.

[11]  Roland Eils,et al.  Dynamics within the CD95 death-inducing signaling complex decide life and death of cells , 2010, Molecular systems biology.

[12]  S-C Sun.  CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes , 2010, Cell Death and Differentiation.

[13]  P. Muriel.  NF‐κB in liver diseases: a target for drug therapy , 2009, Journal of applied toxicology : JAT.

[14]  Marcus Schuchmann,et al.  Knockout of myeloid cell leukemia‐1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes , 2009, Hepatology.

[15]  A. Bosserhoff,et al.  Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma , 2009, The Journal of Experimental Medicine.

[16]  G. Gores,et al.  Cellular and molecular mechanisms of liver injury. , 2008, Gastroenterology.

[17]  William M. Lee,et al.  Acute liver failure: Summary of a workshop , 2007, Hepatology.

[18]  P. Ligoxygakis,et al.  CYLD: A Multifunctional Deubiquitinase , 2007, Fly.

[19]  P. Galle,et al.  Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD , 2007, The Journal of experimental medicine.

[20]  L. Xue,et al.  Tumor suppressor CYLD regulates JNK-induced cell death in Drosophila. , 2007, Developmental cell.

[21]  F. Giancotti,et al.  Faculty Opinions recommendation of Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. , 2006 .

[22]  Ramin Massoumi,et al.  Cyld Inhibits Tumor Cell Proliferation by Blocking Bcl-3-Dependent NF-κB Signaling , 2006, Cell.

[23]  Shao-Cong Sun,et al.  Negative Regulation of JNK Signaling by the Tumor Suppressor CYLD* , 2004, Journal of Biological Chemistry.

[24]  R. Schwabe,et al.  Differential requirement for c‐Jun NH2‐terminal kinase in TNF‐α‐and Fas‐mediated apoptosis in hepatocytes , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  A. Rao.  Faculty Opinions recommendation of Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. , 2003 .

[26]  René Bernards,et al.  Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB , 2003, Nature.

[27]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[28]  M. Peter,et al.  The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.

[29]  S. Pollefeyt,et al.  Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. , 2002, Gastroenterology.

[30]  C. Trautwein,et al.  Cytokine regulation of pro- and anti-apoptotic genes in rat hepatocytes: NF-kappaB-regulated inhibitor of apoptosis protein 2 (cIAP2) prevents apoptosis. , 2002, Journal of hepatology.

[31]  Michael Karin,et al.  NF-κB at the crossroads of life and death , 2002, Nature Immunology.

[32]  Michael Karin,et al.  NF-kappaB at the crossroads of life and death. , 2002, Nature immunology.

[33]  Francesca Zazzeroni,et al.  Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling , 2001, Nature.

[34]  J. Jones,et al.  Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. , 2001, Nature.

[35]  A. Kahn,et al.  Differential protective effects of Bcl-xL and Bcl-2 on apoptotic liver injury in transgenic mice. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[36]  G. Cheng,et al.  NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  W. Zong,et al.  The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis , 1999 .

[38]  G. Gores,et al.  Death receptors in liver biology and pathobiology , 1999, Hepatology.

[39]  C Gélinas,et al.  The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. , 1999, Genes & development.

[40]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[41]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[42]  Christian Stehlik,et al.  Nuclear Factor (NF)-κB–regulated X-chromosome–linked iap Gene Expression Protects Endothelial Cells from Tumor Necrosis Factor α–induced Apoptosis , 1998, The Journal of experimental medicine.

[43]  A. S. Loginov,et al.  Mechanisms of cycloheximide‐induced apoptosis in liver cells , 1997, FEBS letters.

[44]  M. Malim,et al.  Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Gerritsen,et al.  Novel Inhibitors of Cytokine-induced IκBα Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo* , 1997, The Journal of Biological Chemistry.

[46]  M. Gerritsen,et al.  Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. , 1997, The Journal of biological chemistry.

[47]  D. White,et al.  Rel/NF-kappaB/IkappaB proteins and cancer. , 1996, Oncogene.

[48]  P. Galle,et al.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage , 1995, The Journal of experimental medicine.

[49]  M. Leist,et al.  Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. , 1995, The American journal of pathology.

[50]  W. Reutter,et al.  Galactosamine-induced sensitization to the lethal effects of endotoxin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.